Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: volatility sketched a sometimes contradictory picture of the sector before the session closed positive

August 24, 2018 5:33pm

Every time, I hear about or see a new high – I say bye!

Our posts keep clients at the tip of actionable intelligence while surfacing risks and opportunities not already priced into the market …

No hard sell, get on the list for a 30 day trial!

Henry’omics:

As noted in the pre-open – today was number’s day - weekly jobless claims fell to 210,000, near levels not seen since 1969. Core durable goods orders rose 1.4% in July, more than the expected 0.4% increase.

Investors are faced with trade fears as the U.S. and China concluded talks this week with no major breakthrough as tariffs against the U.S. and Chinese goods came into effect from both sides.

“Our” universe of stocks – sidestepped downturns to conclude on a positive note as the second hour of the sector’s open had slipped negative yet rebounded at the mid-day barely positive.

As I had alluded – trepidation is “in the session” - next week will be telling a story of a down slide!

From the pre-open newsletter: “play the stocks you have, it’s still about protecting current holdings and funding your future portfolios – it’s NOT a time to take on more risk!”

I also stated, “I’d stake my moves to the sidelines.”

Of the 45 companies covered on Friday; 19 downside equities finished in a range of -0.05% (VTGR) to -5.56% (FIXX) while the 24 upside equities oscillated from +0.60% (NTLA) to +5.95% (MDXG) with 2 flat closes (BSTG and PSTI).

Daily analytics and metrics:

The DOW closed up +133.97 points or +0.52% to 25,790.35
The S&P closed up +17.71 points or +0.62% to %2,874.69
The NASDAQ closed up +67.52 points or +0.86% to 7,945.98

The advance/decline line scenario of 45 covered companies:

The open was positive with an A/DL of 32/10 and 3 flats;
The second hour slipped negative with an A/DL of 20/24 and 1 flat;
The mid-day was barely positive with an A/DL of 22/21 and 2 flats;
The close was positive with an A/DL of 24/19 and 2 flats;

The five (5) largest trend lines:

… The greatest volume to the downside: SGMO, IONS, ALNY, BMRN and GBT

… Upside volume was weighted to: MDXG, VSTM, XOPN, ONVOP and VCEL

… Leadership ($) to the downside: RENE.L (-$3.00), BLUE (-$2.35), SAGE (-$1.52), IONS (-$1.41) and FIXX (-$0.96)

… Best moves ($) to the upside: SLDB (+$0.90), VCEL (+$0.68), BLFS (+$0.55), FATE (+$0.50) and QURE (+$0.49)

The iShares NASDAQ Biotechnology (IBB) closed:

Friday was up +0.17 %
Thursday was down -0.58%
Wednesday was up +0.71%
Tuesday was up +0.93%
Monday was down -0.17%
Last Friday was up +0.02%

August sessions:

Friday closed POSITIVE with 19 decliners, 24 advancers and 2 flats;

Thursday closed NEGATIVE with 26 decliners, 16 advancers and 3 flats;

Wednesday closed POSITIVE with 12 decliners, 32 advancers and 1 flat;

Tuesday closed POSITIVE with 9 decliners, 36 advancers and 0 flat;

Monday closed POSITIVE with 16 decliners, 23 advancers and 6 flat;

Friday closed POSITIVE with 18 decliners, 24 advancers and 3 flat;

Thursday closed POSITIVE with 16 decliners, 27 advancers and 2 flat;

Wednesday closed NEGATIVE with 36 decliners, 6 advancers and 3 flat;

Tuesday closed POSITIVE with 13 decliners, 28 advancers and 4 flat;

Monday closed NEGATIVE with 24 decliners, 19 advancers and 2 flat;

Friday closed POSITIVE with 19 decliners, 24 advancers and 2 flat;

Thursday closed POSITIVE with 14 decliners, 29 advancers and 2 flat;

Wednesday closed NEGATIVE with 25 decliners, 16 advancers and 4 flat;

Tuesday closed POSITIVE with 14 decliners, 29 advancers and 2 flat;

Monday closed POSITIVE with 19 decliners, 24 advancers and 2 flat;

Friday closed NEGATIVE with 37 decliners, 4 advancers and 4 flat;

Thursday closed POSITIVE with 16 decliners, 27 advancers and 2 flat;

Wednesday (8/1) closed NEGATIVE with 23 decliners, 21 advancers and 1 flat;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.